Is depression an appropriate response to having cancer? A discussion of diagnostic criteria and treatment decisions

Primary Care Companion to the Journal of Clinical Psychiatry

Volumn 9, Issue 5, 2007, Pages 382-387

  Gross, Anne F ^a,b,c   Smith, Felicia A ^b   Stern, Theodore A ^a,b  

^a HARVARD MEDICAL SCHOOL   (United States)

^b MASSACHUSETTS GENERAL HOSPITAL   (United States)

^c MCLEAN HOSPITAL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMFEBUTAMONE; AMPHETAMINE DERIVATIVE; ANTIDEPRESSANT AGENT; ANTIHISTAMINIC AGENT; CIMETIDINE; CITALOPRAM; CODEINE; DULOXETINE; FLUOXETINE; FLUVOXAMINE; HYDROCODONE; METHADONE; METHYLPHENIDATE; MIRTAZAPINE; MONOAMINE OXIDASE INHIBITOR; NEUROLEPTIC AGENT; OXYCODONE; PAROXETINE; PHENYTOIN; PROPRANOLOL; QUINIDINE; SEROTONIN UPTAKE INHIBITOR; SERTRALINE; THEOPHYLLINE; TRAMADOL; TRICYCLIC ANTIDEPRESSANT AGENT; UNINDEXED DRUG; VALPROIC ACID; VENLAFAXINE; WARFARIN;

ANOREXIA; ANXIETY; BRAIN METASTASIS; CANCER MORTALITY; CANCER RISK; CLINICAL PRACTICE; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; COPING BEHAVIOR; DECREASED APPETITE; DELIRIUM; DEPRESSION; DIAGNOSTIC AND STATISTICAL MANUAL OF MENTAL DISORDERS; DIARRHEA; DIASTOLIC BLOOD PRESSURE; DISEASE SEVERITY; DIZZINESS; DROWSINESS; DRUG ANTAGONISM; DRUG HALF LIFE; DRUG METABOLISM; DRUG POTENCY; FOOD DRUG INTERACTION; GASTROINTESTINAL SYMPTOM; HEADACHE; HEART ARRHYTHMIA; HUMAN; HYPERTENSION; HYPOTENSION; INCREASED APPETITE; INSOMNIA; MEDICAL DECISION MAKING; MORBIDITY; NAUSEA; NOTE; ORTHOSTATIC HYPOTENSION; PATIENT COMPLIANCE; PSYCHOEDUCATION; QUALITY OF LIFE; SEDATION; SEXUAL DYSFUNCTION; SIDE EFFECT; SLEEP DISORDER; SUICIDAL BEHAVIOR; SUPPORT GROUP; TACHYCARDIA; UNSPECIFIED SIDE EFFECT; URINE RETENTION; VOMITING; WEIGHT GAIN; XEROSTOMIA;

EID: 36248983085     PISSN: 15235998     EISSN: 1555211X     Source Type: Journal    
DOI: 10.4088/PCC.v09n0508     Document Type: Note

References (25)

1. Zabora J, BrintzenhofeSzoc K, Curbow B, et al. The prevalence of psychological distress by cancer site. Psychooncology 2001;10:19-28
2. Weisman AD, Worden JW, Sobel HJ. Psychosocial Screening and Interventions With Cancer Patients: A Research Report. Boston, Mass: Harvard Medical School; 1980
3. Cohen L, de Moor C, Devine D, et al. Endocrine levels at the start of treatment are associated with subsequent psychological adjustment in cancer patients with metastatic disease. Psychosom Med 2001;63:951-958
4. Kessler RC, Chiu WT, Demler O, et al. Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 2005;62:617-627
5. Miller K, Massie MJ. Depression and anxiety. Cancer J 2006;12:388-397
6. Reuter K, Raugust S, Marschner N, et al. Differences in prevalence rates of psychological distress and mental disorders in inpatients and outpatients with breast and gynecological cancer. Eur J Cancer Care (Engl) 2007;16:222-230
7. Pirl WF. Depression in men receiving androgen deprivation therapy for prostate cancer: a pilot study. Psychooncology 2002;11:518-523
8. Reiche E, Nunes SO, Morimoto HK. Stress, depression, the immune system, and cancer. Lancet Oncol 2004;5:617-625
9. Jehn CF. Biomarkers of depression in cancer patients. Cancer 2006;107:2723-2729
10. Onitilo A, Nietert PJ, Egede LE. Effect of depression on all-cause mortality in adults with cancer and differential effects by cancer site. Gen Hosp Psychiatry 2006;28:396-402
11. Jenkins V. Information needs of patients with cancer: results from a large study in the UK cancer centers. Br J Cancer 2001;84:48-51
12. Baile WF, Buckman R. SPIKES: a six step protocol for delivering bad news: approach to the patient with cancer. Oncologist 2000;5:302-311
13. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders, Fourth Edition, Text Revision. Washington, DC: American Psychiatric Association; 2000
14. Pasquini M, Biondi M. Depression in cancer patients: a critical review. Clin Pract Epidemiol Ment Health 2007;3:2
15. Block S. Assessing and managing depression in the terminally ill patient. Ann Int Med 2000;132:209-218
16. Chochinov HM, Wilson KG, Enns M, et al. "Are you depressed?": screening for depression in the terminally ill. Am J Psychiatry 1997;154:674-676
17. Osborn RL. Psychosocial interventions for depression, anxiety, and quality of life in cancer survivors: meta-analyses. Int J Psychiatry Med 2006;36:13-34
18. Fisch M. Treatment of depression in cancer. J Natl Cancer Inst Monogr 2004:105-111
19. Owen JE. Use of health-related and cancer-specific support groups among adult cancer survivors. Cancer 2007;109:2580-2589
20. Carlson L, Butlz B. Efficacy and medical cost offset of psychosocial interventions in cancer care: making the case for economic analysis. Psychooncology 2004;13:837-849
21. Berney A. Psychopharmacology in supportive care of cancer: a review for the clinician, 3: antidepressants. Support Care Cancer 2000;8:278-286
22. Bernard S, Bruera E. Drug interactions in palliative care. J Clin Oncol 2000;18:1780-1799
23. Rozans M, Dreisbach A, Lertora JJ, et al. Palliative uses of methylphenidate in patients with cancer: a review. J Clin Oncol 2002;20:335-339
24. Nemeroff C, Schatzberg A. Textbook of Psychopharmacology, 2nd edition. Washington, DC: American Psychiatric Press; 1998
25. Davis MP. Does trazodone have a role in palliating symptoms? Support Care Cancer 2007;15:221-224